MEDICINE DETAILS
Lynparza
Active ingredient: Olaparib
Neutral reference profile for an independent medicine-access consultancy enquiry about Lynparza (Olaparib). No medicine is offered for sale.
NEXT STEP
Choose the strength and pack
✓ If you are unsure, choose “I do not know”.
These options are not medical advice, a dosing recommendation, stock confirmation or a sale offer.
ABOUT THIS MEDICINE
What is Lynparza used for?
Lynparza (olaparib) is indicated as a poly (ADP-ribose) polymerase (PARP) inhibitor for the treatment of people with:
- Advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer:
- With an abnormal BRCA gene. It is used alone as maintenance treatment after the cancer has responded to your first treatment with platinum-based chemotherapy.
- With an abnormal BRCA gene or a positive laboratory tumor test for genomic instability called HRD. It is used in combination with another anti-cancer medicine, bevacizumab, as maintenance treatment after the cancer has responded to your first treatment with platinum-based chemotherapy.
- As maintenance treatment, when the cancer has come back. It is used after the cancer has responded to treatment with platinum-based chemotherapy.
- With an abnormal inherited BRCA gene, and have received treatment with 3 or more prior types of chemotherapy medicines.
- Human epidermal growth factor receptor 2 (HER2)-negative breast cancer with an abnormal inherited BRCA gene, that has spread to other parts of the body (metastatic). You should have received chemotherapy medicines, either before or after your cancer has spread. If you have HR-positive disease, you should have been treated with hormonal therapy.
- Metastatic pancreatic cancer with an abnormal inherited BRCA gene. It is used as a maintenance treatment after your cancer has not progressed on at least 16 weeks of treatment with platinum-based chemotherapy.
- Prostate cancer with abnormal genes called homologous recombination repair (HRR genes). It is used when the cancer is metastatic, and no longer responds to a medical or surgical treatment that lowers testosterone, and has progressed after treatment with enzalutamide or abiraterone.
It is available in tablet form, containing either 100 mg or 150 mg of olaparib.
This information is general and is not medical advice. Talk to your doctor or pharmacist about any treatment decision.
RECORDED PRODUCT PROFILE
Lynparza identity, dosage form and pack information.
The details below are assembled from current catalogue records. They must still be checked against the prescription, medicine box and an official regulatory record.
Recorded strength and pack options
Each row is shown only to help identify the product; it is not stock confirmation or a sale offer.
-
100 mg · 112 tablets Catalogue organisation: AstraZeneca GmbH GB Spezialvertrieb
-
150 mg · 112 tablets Catalogue organisation: AstraZeneca GmbH GB Spezialvertrieb
OFFICIAL SOURCES
Check the Lynparza record at an official source.
Search for “Lynparza” or “Olaparib”. Finding a product in one source does not by itself confirm stock, authorisation in a particular country or suitability for a patient.
OFFICIAL EXTERNAL SOURCE
European Medicines Agency (EMA)
Search medicines evaluated by EMA by brand name or active substance. EMA also links to national registers for nationally authorised products.
↗ OFFICIAL EXTERNAL SOURCE Drugs@FDASearch FDA-approved human drug records by brand name or active ingredient, including current labelling where available.
↗SERVICE BOUNDARY
Information checking and independent enquiry support for Lynparza.
OrphanDrug helps organise the product identity and recorded strength and pack details for an enquiry. It does not sell, take payment for, prescribe, import, dispense or deliver medicines.
Clinical decision: Only a qualified healthcare professional who has assessed the patient can decide whether a product, form or dose is appropriate.
CLEAR ANSWERS
Frequently asked questions about Lynparza
01What is Lynparza?＋
This directory record associates the brand name Lynparza with the active ingredient Olaparib. The brand and ingredient are shown for product identification only, not as treatment or dosing advice.
02Which Lynparza strengths and packs are recorded?＋
The catalogue currently shows: 100 mg · 112 tablets; 150 mg · 112 tablets. Check the complete strength, dosage form and pack description against the prescription and medicine box.
03Who manufactures Lynparza?＋
Catalogue records currently name: AstraZeneca GmbH GB Spezialvertrieb. This field may identify a manufacturer, marketing-authorisation holder, marketing company or supplier; confirm the exact role on the pack leaflet and official regulatory record.
04Do the listed options confirm stock or access?＋
No. A catalogue record does not confirm current stock, authorisation in a particular country, clinical suitability, import permission or access.
05What affects a possible estimated medicine cost for Lynparza?＋
A possible cost depends on the exact strength, dosage form, pack, quantity, destination and regulatory jurisdiction. Any amount provided after an enquiry is an indicative medicine-cost estimate only, not a selling price for Lynparza, payment request, stock guarantee or binding offer.
06Can I buy Lynparza from this website?＋
No. This website does not sell, take payment for, prescribe, import, dispense or deliver medicines. The form creates an independent consultancy enquiry only.